Shanghai, China

Zongqin Xia

This inventor holds 5 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Phytopharm Plc. Active years: 2001-2009.

USPTO Granted Patents = 5 

% Patents Active = 20.0

 

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2001-2009

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Zongqin Xia: Innovator in Cognitive Dysfunction Treatments

Introduction

Zongqin Xia is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cognitive dysfunction treatments. With a total of 5 patents, his work focuses on innovative solutions for improving cognitive health.

Latest Patents

Zongqin Xia's latest patents include groundbreaking inventions such as "5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia." This invention discloses the use of sapogenin derivatives in treating cognitive dysfunction and similar conditions. It also outlines methods of treatment and pharmaceutical compositions. Another notable patent is "Smilagenin and its use," which reveals the application of smilagenin in treating cognitive dysfunction and related conditions, along with methods of treatment and pharmaceutical compositions.

Career Highlights

Zongqin Xia is currently associated with Phytopharm Plc, where he continues to advance research in cognitive health. His innovative approaches have garnered attention in the scientific community, contributing to the development of effective treatments.

Collaborations

Zongqin Xia has collaborated with notable colleagues, including Yaer Hu and Ian Duncan Rubin. Their combined expertise enhances the research and development efforts in their field.

Conclusion

Zongqin Xia's contributions to the treatment of cognitive dysfunction are noteworthy. His innovative patents and collaborations reflect his commitment to improving cognitive health through scientific advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…